Search / 14 results found

  • Updated

KING OF PRUSSIA, Pa., June 8, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the Centers for Medicare & Medicaid Services (CMS) has approved Hizentra for coverage under Medicare Part B for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The new coverage, which is effective for dates of service on or after July 18, 2021, will reduce out-of-pocket costs for patients and includes coverage of the self-infusion pump, supplies, medication and nurse training. Hizentra will be the only self-infusion treatment for CIDP covered under the same benefit category as other Ig CIDP treatment options.

As 2020 unfolded, the world learned just how quickly the novel coronavirus COVID-19 could spread. The World Health Organization noted that, by September 2020, nearly 30 million people across the globe had contracted the virus, and that was before the resurgence of the virus in mid-fall.

For many women, giving birth to a baby may trigger an assortment of emotions including joy, excitement, anxiety and even fear. But it could also lead to something you may not expect. Many new mothers experience a mild form of depression, sometimes called “the baby blues.” Others, however, can experience a more severe, long-lasting medical condition known as postpartum depression.